No CrossRef data available.
Article contents
P03-360 - The Effect of Lamotrigine Augmentation to Haloperidol Deaconate in the Treatment of Resistant Schizophrenia: Randomized, Double-Blind, Placebo-Controlled, Study
Published online by Cambridge University Press: 17 April 2020
Abstract
Core share and HTML view are not available for this content. However, as you have access to this content, a full PDF is available via the ‘Save PDF’ action button.
Objective
The current paper reports on a double-blind, randomized study of the role of lamotrigine as an augmentation agent to haloperidol deaconate in the treatment of out patient's schizophrenia with verbal resistant hallucinosis.
Method
Three hundred fifty patients were studied. The patients were then randomly divided into two groups on 175 subjects in each group. First group patients received either haloperidol deaconate 100 mg in month intramuscular and lamotrigine 150-200 mg in day per so for 12 weeks. Second group patients were given haloperidol deaconate 100 mg in month intramuscular and placebo per os for 12 weeks. The expressiveness of psychopathology was estimated on PANSS.
Results
75 (44%) of the 168 first group participants responded by 12 weeks, versus one (0.6%) of the 167 second group treated participants.
Conclusions
Our data suggest that haloperidol with the combination of lamotrigine was more effective than placebo.
- Type
- Psychopharmacological treatment and biological therapies
- Information
- Copyright
- Copyright © European Psychiatric Association 2010
You have
Access
Comments
No Comments have been published for this article.